title: Notable deals in the pharmaceutical industry in the fourth quarter of 2016.
abstract: During the fourth quarter of 2016, Cortellis Competitive Intelligence had 889 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This was an increase on both the last quarter (865) but a decrease from the same quarter for the previous year (915). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestones, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter's pharmaceutical licensing activity.
authors.affiliation: Clarivate Analytics, London, UK. paul.dsouza@clarivate.com.
authors.forename: P
authors.initials: P
authors.lastname: D'Souza
mesh_terms: D003132:Commerce / Q000191:economics* / Q000639:trends; D016527:Drug Costs / Q000639:trends; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D015507:Drugs, Investigational / Q000191:economics*; D006801:Humans; D000071220:Pharmaceutical Research / Q000191:economics* / Q000639:trends; D012109:Research Support as Topic / Q000191:economics* / Q000639:trends; D013997:Time Factors
chemical_list: D015507:Drugs, Investigational
keywords: Deals; Milestones; Pharmaceutical industry